Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01092624 · ClinicalTrials.gov registry record · Phase 4
Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse
A Phase 4 study, sponsored by Hartford Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 94
- Enrollment target
NCT01092624 is a Phase 4 study that was terminated before completion, run by Hartford Hospital. The registered enrollment target is 94 participants.
The verdict
NCT01092624, a Phase 4 study, was terminated before completion, sponsored by Hartford Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 94 participants
- Enrollment target
Study Summary
This study will evaluate the effect of pessary therapy, with and without Solifenacin (Vesicare), on symptoms of over active bladder and bladder function in women with overactive bladder symptoms and pelvic organ prolapse. Study Hypotheses: Null hypothesis, HO: Reduction of anterior vaginal wall prolapse and treatment with solifenacin does not improve overactive bladder symptoms more than reduction of anterior vaginal wall prolapse and placebo. Alternate hypothesis, HA: Reduction of anterior vaginal wall prolapse and treatment with solifenacin does improve overactive bladder symptoms more than reduction of anterior vaginal wall prolapse and placebo.
Interventions
- DRUG Placebo
- DRUG Solifenacin
- DEVICE Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01092624
The ClinicalTrials.gov registry entry for NCT01092624 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01092624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01092624 about?
NCT01092624 is a clinical study titled "Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse". This study will evaluate the effect of pessary therapy, with and without Solifenacin (Vesicare), on symptoms of over active bladder and bladder function in women with overactive bladder symptoms and pelvic organ prolapse. Study Hypotheses: Null hypothesis, HO: Reduction of anterior vaginal wall pr...
What is the current status of trial NCT01092624?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 94 participants. The study started on 2010-03. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01092624?
The interventions under investigation include: Placebo (DRUG), Solifenacin (DRUG), Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex (DEVICE).
Who is sponsoring clinical trial NCT01092624?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.